Biggest Small Cap Losers: Exide Technologies (NASDAQ:XIDE), Generex Biotechnology Corporation (OTCMKTS:GNBT)

Posted by Chris Bell May 27, 2013 0 Comment 1151 views


Northern, WI 05/27/2013 (GDPInsider) – Exide Technologies (NASDAQ:XIDE) is down big in today’s trading after starting the day at 0.78, level with the previous close of the same amount. The stock is down 42.58% on strong trading volume of 27.142 million. Average volume is 2.546 million and the surge in trading activity downward means that XIDE is now 88.07% below its 52-week high of 3.77 and 29.72% below its 52-week low of 0.64.

XIDE is facing strong investor apathy after it was hit with a class action lawsuit by some investors. The lawsuit is being led by The Rosen Law Firm, P.A. and a recent announcement by the firm reminded investors that the lead plaintiff deadline is June 14, 2013. Investors are alleging that XIDE failed to disclose several key bits of information, including the release of potentially fatal levels of arsenic near its Vernon, California battery recycling facility.

In the wake of the allegation investors have moved to unload their interest in XIDE and the stock is now dangerously low with a RSI of 22.36. The stock is trading 70.88% below its 50-day simple moving average and 44.88% below its 20-day simple moving average.

Is XIDE a solid investment at these levels? Get exclusive data and trends here.

Generex Biotechnology Corporation (OTCMKTS:GNBT) is down 19.43% in today’s trading after starting the day level with its previous close of 0.04. The stock seems to have taken a hit on investor sell-off with volume clocking in at 15.872 million, a 751.37% increase on average volume of 1.864 million. Current market valuation has taken GNBT 74.08% below its 52-week high of 0.12 and 55.50% above its 52-week low of 0.02.

The biotechnology company which focuses on metabolic and immunological diseases, recently announced plans to present three presentations demonstrating the superiority of the AE37 breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. The presentations are slated to take place at the annual meeting of the American Society of Clinical Oncology over the period May 31 – June 4, 2013.

GNBT is up 2.20% on its SMA20 and 3.08% on its SMA50. The stock has a RSI of 50.00 indicating that the stock is neither oversold nor overbought at current market valuation.

How Should Investors Trade GNBT Now? Get exclusive insights and updates here.

 

 

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.

 


About Chris Bell

Chris Bell is an investing reporter for GDP Insider. Chris covers financial markets and Wall Street, concentrating on developments affecting individual investors and their portfolios. Chris is also over consumer reporter and covers a wide variety of issues ranging from housing to immigration to urban poverty. Chris graduated from the University of Scranton with a degree in Communication and Philosophy. Chris's diligent investigations earned him the honor of being named "Best Reporter" once by the Headliners Foundation of Texas and once by the Houston Press Club.

View all post by Chris Bell Visit author's website

Write Your Comment